115 related articles for article (PubMed ID: 21678640)
1. [Identification of K-RAS mutations in colorectal cancer patients in Israel].
Segal G; Liebermann N; Klang S; Siegelmann-Daniel N; Beit-Or A; Klien B; Shoushan-Gutman L
Harefuah; 2011 May; 150(5):447-50, 491. PubMed ID: 21678640
[TBL] [Abstract][Full Text] [Related]
2. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Kim R; Kubal T
Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
[No Abstract] [Full Text] [Related]
3. [Personalized medicine--the future is already here].
Abadi-Korek I; Shemer J
Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
[TBL] [Abstract][Full Text] [Related]
4. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
5. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
8. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
10. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
11. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
12. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC; Farina G; Rossi A; Martelli O; Torri V
J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
[No Abstract] [Full Text] [Related]
13. Clinical relevance of KRAS mutations in codon 13: Where are we?
Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
Cancer Lett; 2014 Feb; 343(1):1-5. PubMed ID: 24051306
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
15. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
16. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
17. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Chen J; Ye Y; Sun H; Shi G
Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
[TBL] [Abstract][Full Text] [Related]
18. [Biology applied to cancer treatments: the example of colorectal cancer].
Lièvre A; Laurent-Puig P
Rev Prat; 2010 Oct; 60(8):1100-2. PubMed ID: 21197742
[No Abstract] [Full Text] [Related]
19. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
20. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
